Completed PHASE1 INTERVENTIONAL 1-arm NCT01595828

Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome (CAPITAIN)

An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)

Sponsor: Kowa Research Europe

Conditions Metabolic Syndrome

Interventions Pitavastatin

Updated 5 times since 2017 Last updated: Jul 19, 2013 Started: Oct 31, 2010 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01595828, this PHASE1 trial focuses on Metabolic Syndrome and remains completed. Sponsored by Kowa Research Europe, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kowa Research Europe

Data source: Kowa Research Europe

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wokingham, United Kingdom